CA2400657A1 - Derives de quinoline utilises comme antagonistes alpha2 - Google Patents

Derives de quinoline utilises comme antagonistes alpha2 Download PDF

Info

Publication number
CA2400657A1
CA2400657A1 CA002400657A CA2400657A CA2400657A1 CA 2400657 A1 CA2400657 A1 CA 2400657A1 CA 002400657 A CA002400657 A CA 002400657A CA 2400657 A CA2400657 A CA 2400657A CA 2400657 A1 CA2400657 A1 CA 2400657A1
Authority
CA
Canada
Prior art keywords
alkyl
phenyl
compound
alkoxy
mono
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002400657A
Other languages
English (en)
Inventor
Mia Engstrom
Juha-Matti Savola
Iisa Hoglung
Andrei Tauber
Antti Haapalinna
Harri Salo
Anna-Marja Hoffren
Siegfried Wurster
Jukka Sallinen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Orion Oyj
Juvanita Pharma Ltd Oy
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2400657A1 publication Critical patent/CA2400657A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C07D215/44—Nitrogen atoms attached in position 4 with aryl radicals attached to said nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D219/00—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems
    • C07D219/04—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • C07D219/08—Nitrogen atoms
    • C07D219/10—Nitrogen atoms attached in position 9
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/16—Ring systems of three rings containing carbocyclic rings other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)

Abstract

La présente invention concerne un composé représenté par la formule (I), dans laquelle A, Ra, Rb, R¿1? à R¿5?, m et t sont tels que définis dans les spécifications, un sel ou un ester pharmaceutiquement acceptable de ce composé, qui convient comme antagoniste alpha 2. Ces composés conviennent pour le traitement de maladies et de pathologies pour lesquelles les antagonistes alpha 2 sont réputés être efficaces.
CA002400657A 2000-03-01 2001-02-28 Derives de quinoline utilises comme antagonistes alpha2 Abandoned CA2400657A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FI20000480 2000-03-01
FI20000480A FI20000480A0 (fi) 2000-03-01 2000-03-01 Kinoliini- ja naftaleenijohdannaisia alfa-2 antagonisteina
PCT/FI2001/000203 WO2001064645A2 (fr) 2000-03-01 2001-02-28 Derives de quinoline utilises comme antagonistes alpha2

Publications (1)

Publication Number Publication Date
CA2400657A1 true CA2400657A1 (fr) 2001-09-07

Family

ID=8557801

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002400657A Abandoned CA2400657A1 (fr) 2000-03-01 2001-02-28 Derives de quinoline utilises comme antagonistes alpha2

Country Status (21)

Country Link
EP (1) EP1263733A2 (fr)
JP (1) JP2003525274A (fr)
KR (1) KR20020089372A (fr)
CN (1) CN1468224A (fr)
AR (1) AR034249A1 (fr)
AU (1) AU2001239331A1 (fr)
BR (1) BR0108816A (fr)
CA (1) CA2400657A1 (fr)
CZ (1) CZ20022880A3 (fr)
EE (1) EE200200490A (fr)
FI (1) FI20000480A0 (fr)
HU (1) HUP0204458A3 (fr)
IL (1) IL151093A0 (fr)
MX (1) MXPA02008402A (fr)
NO (1) NO20024159D0 (fr)
PE (1) PE20011084A1 (fr)
PL (1) PL357874A1 (fr)
RU (1) RU2002125944A (fr)
SK (1) SK12332002A3 (fr)
WO (1) WO2001064645A2 (fr)
ZA (1) ZA200206956B (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003203148A1 (en) * 2002-02-05 2003-09-02 High Point Pharmaceuticals, Llc Novel aryl- and heteroarylpiperazines
WO2003082866A1 (fr) 2002-04-03 2003-10-09 Orion Corporation Composes polycycliques comme antagonistes puissants des recepteurs $g(a)2-adrenergiques
ES2367481T3 (es) * 2002-04-03 2011-11-03 Orion Corporation Uso de un antagonista del adrenoreceptor alfa2 para enfermedades relacionadas con el snc.
CA2484959A1 (fr) * 2002-04-30 2003-11-13 Yungjin Pharmaceutical Co., Ltd. Derives de la quinoline inhibiteurs de la caspase-3, preparation servant a les obtenir, et preparations pharmaceutiques les comprenant
WO2004067513A1 (fr) * 2003-01-27 2004-08-12 Oy Juvantia Pharma Ltd Antagonistes pour recepteurs alpha-2 adrenergiques
ATE536344T1 (de) 2005-07-04 2011-12-15 High Point Pharmaceuticals Llc Histamine h3 receptor antagonisten
WO2007053436A1 (fr) 2005-10-31 2007-05-10 Janssen Pharmaceutica N.V. Piperazines et piperidines substituees en tant que modulateurs du recepteur du neuropeptide y2
WO2007078335A2 (fr) * 2005-12-21 2007-07-12 Decode Genetics, Ehf. Inhibiteurs de biaryl-azote-heterocycle de lta4h pour traiter l'inflammation
JP2009537602A (ja) * 2006-05-22 2009-10-29 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 薬剤として用いるための置換ピラジノン誘導体
EP2038256A1 (fr) 2006-05-23 2009-03-25 TransTech Pharma, Inc 6-(4-cyclopropylpiperazin-1-yl)-2'-methyl-[3,4']-bipyridine et son utilisation comme medicament
WO2007137968A1 (fr) 2006-05-29 2007-12-06 High Point Pharmaceuticals, Llc Benzodioxolylcyclopropylpipérazinylpyridazines
EP2014656A3 (fr) 2007-06-11 2011-08-24 High Point Pharmaceuticals, LLC Nouveaux antagonistes d'hétéocycliques h3
TWI457122B (zh) 2007-07-20 2014-10-21 Orion Corp 作為用於治療周邊和中央神經系統疾病之alpha2C拮抗劑的2,3－二氫苯並[1,4]戴奧辛－2－基甲基衍生物
EP2356106A1 (fr) 2008-10-07 2011-08-17 Schering Corporation Analogues de biaryl-spiroaminooxazoline en tant que modulateurs de récepteur adrénergique alpha2c
TW201024282A (en) 2008-11-20 2010-07-01 Orion Corp New pharmaceutical compounds
CN103180297A (zh) * 2009-12-11 2013-06-26 基因密码公司 使用gdnf家族配体(gfl)模拟剂或ret信号传导通路活化剂促进神经细胞存活的方法
CN103524413B (zh) * 2012-07-04 2016-04-20 江苏先声药物研究有限公司 氢化吖啶衍生物及其应用
JOP20200052A1 (ar) * 2013-12-19 2017-06-16 Bayer Pharma AG بيبريدينيل تتراهيدرو كوينولينات مستبدلة واستخدامها كمعضدات مستقبل أدريني ألفا- 2c
JP6483804B2 (ja) 2014-03-31 2019-03-13 ミレクス ファーマシューティカルズ， エルエルシーＭｉｒｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｌｌｃ 新規なｈｄｍｘ阻害剤およびガン治療のためのその使用
WO2016135140A1 (fr) 2015-02-23 2016-09-01 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh Dérivés de 4-aminoquinazoline en tant qu'inhibiteurs de mth1 pour la thérapie du cancer
WO2016135137A1 (fr) 2015-02-23 2016-09-01 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh Dérivés de 4-(phénylamino)quinoléine substitués en tant qu'inhibiteurs de mth1 pour la thérapie du cancer
WO2016135138A1 (fr) 2015-02-23 2016-09-01 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh Dérivés d'oxoquinoléine en tant qu'inhibiteurs de mth1 pour la thérapie du cancer
WO2016135139A1 (fr) 2015-02-23 2016-09-01 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh Dérivés de 2,3-dihydrocyclopenta[b]quinoléine en tant qu'inhibiteurs de mth1 pour la thérapie du cancer
CN107337641B (zh) * 2017-07-01 2020-04-28 广东医科大学 一种4-柔性胺基-2-芳乙烯基喹啉类衍生物及其制备方法和应用
CA3230249A1 (fr) * 2021-09-07 2023-03-16 Paul Gregor Composes et compositions pharmaceutiques comprenant des inhibiteurs d'interactions de peptide amyloide avec des glycosaminoglycanes, procedes de traitement et utilisation de ceux-c

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9510757D0 (en) * 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds

Also Published As

Publication number Publication date
SK12332002A3 (sk) 2003-07-01
WO2001064645A3 (fr) 2001-12-27
IL151093A0 (en) 2003-04-10
PE20011084A1 (es) 2001-10-25
WO2001064645A2 (fr) 2001-09-07
JP2003525274A (ja) 2003-08-26
FI20000480A0 (fi) 2000-03-01
PL357874A1 (en) 2004-07-26
RU2002125944A (ru) 2004-02-27
BR0108816A (pt) 2002-12-10
EE200200490A (et) 2003-12-15
CN1468224A (zh) 2004-01-14
HUP0204458A3 (en) 2004-07-28
AR034249A1 (es) 2004-02-18
HUP0204458A2 (hu) 2003-04-28
NO20024159L (no) 2002-08-30
MXPA02008402A (es) 2003-10-14
KR20020089372A (ko) 2002-11-29
ZA200206956B (en) 2003-12-01
EP1263733A2 (fr) 2002-12-11
CZ20022880A3 (cs) 2003-06-18
AU2001239331A1 (en) 2001-09-12
NO20024159D0 (no) 2002-08-30

Similar Documents

Publication Publication Date Title
CA2400657A1 (fr) Derives de quinoline utilises comme antagonistes alpha2
AU623981B2 (en) 2-(1-piperazinyl)-4-phenylcycloalkano-pyridine derivatives, processes for the production thereof, and pharmaceutical composition containing the same
JP4205430B2 (ja) 疼痛を治療するための、バニロイド受容体アンタゴニストとして、使用するための縮合ピリジン誘導体
AU2010276223A1 (en) Potent small molecule inhibitors of autophagy, and methods of use thereof
US20070197509A1 (en) Compositions and methods for modulating gated ion channels
US20090023773A1 (en) Compositions and methods for modulating gated ion channels
SK279292B6 (sk) Benzimidazolové deriváty 5-ht1a a 5-ht2 antagonist
CZ410397A3 (cs) Deriváty 4-fenylaminothiazolu, způsob jejich přípravy a farmaceutické přípravky, které je obsahují
JPH06145170A (ja) ヘテロ環式化合物、その製法及びこれを含有する高血圧及びうつ血性心不全治療用医薬組成物
CN102209713B (zh) 作为5-羟色胺-6配体的1-(芳磺酰基)-4-(哌嗪-1-基)-1h-苯并咪唑
CN111542522A (zh) 可用作激酶抑制剂的被取代的吡唑并嘧啶
EP1937686A1 (fr) Nouveaux derives antipaludiques de 4-aminoquinoline
ES2254095T3 (es) Derivados de quinolin-4-ilo y su empleo como bloqueantes de suptipos receptores del nmda.
WO2004067513A1 (fr) Antagonistes pour recepteurs alpha-2 adrenergiques
US6593324B2 (en) Dervatives of quinoline as alpha-2 antagonists
ES2230017T3 (es) Derivados de quinolin-4-ilo.
SK42299A3 (en) N-(benzothiazol-2-yl) piperidine-1-ethanamine derivatives, their preparation and application in therapeutics
CA2358586A1 (fr) Derive de tetrahydroindazole servant de ligands pour les recepteurs gabaa .alpha.-5
US6441175B1 (en) 1-(N'-arylalkylaminoalkyl)aminoisoquinolines: a new class of dopamine receptor subtype
JPH04128288A (ja) キノロンカルボン酸誘導体及びその製造方法
JPH0776573A (ja) ヘテロ環化合物、その製造法および剤
Sinha et al. Synthesis and pharmacological evaluation of spiroquinazolinones as anti-inflammatory and analgetic agents
AU2015222590A1 (en) Fused acridine derivative and pharmaceutical composition, preparation method and use thereof
Fur et al. Optimized and convergent synthesis of potent anti-malarial aminoquinoline compounds: easy access to analogs
CZ20003630A3 (cs) 4-Chinolinové deriváty

Legal Events

Date Code Title Description
FZDE Discontinued